

Clinical trials of exenatide other doses

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|--|
| exenatide other doses vs placebo | | | |
| Moretto (DOUBLONS avec drucker) , 2008 [NCT00381342] n=155/78 follow-up: 24 weeks | Exenatide 1020 g daily versus Placebo | - | Parallel groups double blind United States, Puerto Rico, Romania, Russia, India |
| NCT00085969 <i>unpublished</i> [NCT00085969] n=99 follow-up: 28 days | exenatide for 28 days versus placebo | subjects with type 2 diabetes mellitus | double-blind USA |
| Poon , 2005 [NCT00044694] n=NA follow-up: 28 days | exenatide at 2.5, 5.0, 7.5, or 10.0 microg administered b.i.d. for 28 days versus placebo | patients with type 2 diabetes | Parallel groups double-blind |
| exenatide other doses vs placebo (add on MER+/-SU) | | | |
| Fineman , 2003 n=109 follow-up: 28 days | exenatide 3 regimen (0.08 micro g/kg) for 28 days versus placebo | patients with type 2 diabetes treated with diet and a sulfonylurea and/or metformin | Parallel groups double-blind USA |
| exenatide other doses vs glargine | | | |
| HEELA (Davies) , 2009 n=NA follow-up: | exenatide 5C10 g bid versus insulin glargine o.d. (titrated to target fasting plasma glucose 5.6 mmol/l) | Patients (BMI>27 kg/m2) with elevated cardiovascular risk and type 2 diabetes inadequately controlled on two or three oral antidiabetes drugs | |
| exenatide other doses vs insulin glargine (add on MET/SU) | | | |
| Trial 8078 n=NA follow-up: | exenatide versus Insulin Glargine | Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin Is the Next Appropriate Therapy | |

More details and results :

- insulin secretagogues peptides (incretins) for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q381>

- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>

References

Moretto (DOUBLONS avec druker), 2008:

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60 [18803987] [10.1016/j.clinthera.2008.08.006](https://doi.org/10.1016/j.clinthera.2008.08.006)

NCT00085969, :

unpublished

Poon, 2005:

Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D Exenatide improves glycaemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-77 [15929678] [10.1089/dia.2005.7.467](https://doi.org/10.1089/dia.2005.7.467)

Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:317-26 [17705687] [10.1089/dia.2006.0024](https://doi.org/10.1089/dia.2006.0024)

Fineman, 2003:

Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD Effect on glycaemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7 [12882864]

HEELA (Davies), 2009:

Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009 Dec;11:1153-62 [19930005]

Trial 8078, :

Entry terms: nouveau, exenatide, exendin 4, exendin-4, Ex4 peptide, Byetta, AC 2993, AC 2993 LAR,